Business Context and Reporting Period
This Form 8-K Current Report was filed by Skye Bioscience, Inc. on September 14, 2021. The report discloses corporate governance changes regarding the departure of the Principal Accounting Officer and the execution of a new office lease agreement.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on operational and governance events rather than financial performance data.
Material Changes
- Personnel Change: The Company terminated its engagement with RoseRyan, Inc., the firm providing accounting and financial advisory services. Consequently, Richard Janney, the Principal Accounting Officer engaged through RoseRyan, resigned effective September 14, 2021. The resignation is unrelated to any disagreement with the Company or its Board.
- Interim Leadership: Punit Dhillon, the Company's CEO, President, Secretary, and Chair of the Board, will serve as the interim Principal Accounting Officer until a successor is appointed.
- Facility Relocation: On September 1, 2021, the Company moved to new offices at 11250 El Camino Real, Suite 100, San Diego, California. The lease, dated August 25, 2021, covers approximately 2,645 square feet with ROIC California, LLC.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of material risks and contingencies. The departure of the accounting officer is explicitly stated as not being related to any disagreement regarding operations, policies, or practices.
Investor Verification Checklist
- Verify the appointment timeline for a permanent successor to the Principal Accounting Officer.
- Review the terms of the new office lease (Exhibit 99.1) for rental obligations and duration.
- Confirm the status of the Company's financial reporting capabilities during the interim period under CEO Punit Dhillon.